•
HC
HCM
HUTCHMED (China) Limited American Depositary Shares
polygon--
Price Chart
Market Cap
2.72B
Volume
5.50K
52W High
$19.50
52W Low
$11.51
Open
$15.74
Prev Close
$15.85
Day Range
15.61 - 15.74
About HUTCHMED (China) Limited American Depositary Shares
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Latest News
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
GlobeNewswire Inc.•Jan 14
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
GlobeNewswire Inc.•Jan 7
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
GlobeNewswire Inc.•Jan 5
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
GlobeNewswire Inc.•Dec 29
BTK Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
GlobeNewswire Inc.•Dec 17
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
GlobeNewswire Inc.•Dec 17
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight
GlobeNewswire Inc.•Dec 4
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
GlobeNewswire Inc.•Nov 27